Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Ocumension (01477.HK) Demonstrates Strong Operational Resilience, Commercialization Capabilities Reach New Heights
2024-08-12 21:52
OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth
2024-03-21 22:44
Ocumension Releases its 2022 Interim Report with its core product Youshiying® being approved for marketing, continuously accelerating product commercialization
2022-08-26 22:09
Ocumension OT-401 (Product name: YUTIO), a treatment for chronic non-infectious uveitis officially approved for marketing by the National Medical Products Administration
2022-06-23 12:19
Ocumension Acquires all the Equity Interests in Two Ophthalmic Products Mainland China, Further Enhancing its Pipeline Strength
2021-08-25 12:35
Ocumension Therapeutics Announces 2021 Interim Results
2021-08-21 00:19
Ocumension Therapeutics (1477.HK) Reports Revenue Growth in 2020, National Commercial Construction has been started to become outstanding
2021-03-20 18:20
Ocumension Therapeutics Strengthens Pipeline for Posterior Segment Eye Diseases
2020-10-30 10:54
Ocumension Therapeutics Launches Initial Public Offering on Hong Kong Stock Exchange
2020-07-10 21:55
1